Edgewise Therapeutics Inc (EWTX)

NASD · Healthcare · Biotechnology · USA

Edgewise Therapeutics Inc is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.

Edgewise Therapeutics discovers and develops small molecule medicines for muscle diseases. The company has product candidates in clinical trials for muscular dystrophies and cardiomyopathy, and preclinical programs for additional muscle conditions.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Edgewise Therapeutics Inc stock.

Our verdict on EWTX

Not valued: We cannot value this company yet.

ETFs with the most weight in EWTX

17 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Biotechnology

All 600 Biotechnology stocks

Cheaper than EWTX in Biotechnology

129 more in this industry show a wider margin of safety.

Is EWTX undervalued or overvalued?

We do not publish a verdict on EWTX yet. We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.

What is the intrinsic value of EWTX?

We do not publish one (as of the 2026-11-17 close). We are missing a figure this valuation depends on. We would rather say so than show a number built on a guess.